Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
MabPharm (2181 HK)
Watchlist
14
Analysis
Health Care
•
China
Mabpharm Limitied manufactures medical products. The Company produces cancer treatment drugs, immune diseases drugs, biosimilar drugs, and other products. Mabpharm markets its products throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Hansoh Pharmaceutical Group
•
05 Aug 2019 11:11
HK IPO Analytics 1H2019: MS and CICC Stand Out
At the beginning of this year, we at Aequitas Research wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...
Ke Yan, CFA, FRM
Follow
606 Views
Share
bearish
•
Cross Asset Strategy
•
28 Jul 2019 13:24
🇨🇳🇭🇰 That Was The Week That Was • China/Hong Kong 22nd-27th July 2019 @Smartkarma
TW3 CHINA/HONG KONG 22-27 JUNEThis TW3 covers China and Hong Kong and is a companion to the North Asian TW3 published earlier today. The weight of...
Campbell Gunn
Follow
577 Views
Share
bullish
•
Tai Hing
•
13 Jun 2019 12:39
Tai Hing (太興) Trading Update - Edible
Tai Hing (6811 HK) raised US$96m at HK$3.00 per share, below the mid-point of its price range. We have covered the IPO in our previous two...
Zhen Zhou, Toh
698 Views
Share
bearish
•
MabPharm
•
31 May 2019 12:24
MabPharm (迈博医药) Post-IPO Trading Update: Poor Debut for a Reason
MabPharm's IPO was priced near the low end and started trading today. We have highlighted in our earlier note that the company's product pipeline...
Ke Yan, CFA, FRM
Follow
619 Views
Share
bullish
•
China East Education
•
25 May 2019 01:51
ECM Weekly (25 May 2019) - ESR Cayman, Hansoh Pharma, Tai Hing, China East Edu, Haitong UniTrust
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
Zhen Zhou, Toh
643 Views
Share
Previous
1
2
3
Next
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x